Insulin/insulin suspension isophane biosimilar - Wockhardt
Alternative Names: Biphasic insulin isophane biosimilar - Wockhardt; Consegna 30/70; Insulin suspension isophane/insulin biosimilar - Wockhardt; Recombinant (r-DNA) human insulin biphasic - Wockhardt; Wosulin 30/70; Wosulin 50/50Latest Information Update: 28 Sep 2021
At a glance
- Originator Wockhardt
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 1 diabetes mellitus
Most Recent Events
- 28 Sep 2021 Discontinued - Phase-III for Type 1 diabetes mellitus in USA (SC)
- 27 Jul 2020 Wockhardt plans a pilot phase I trial in Healthy volunteers in India (SC, Injection) (CTRI2020-06-026146)
- 22 Apr 2020 Wockhardt plans a bioequivalence phase I trial in Healthy volunteers in India (SC) (CTRI/2020/04/024787)